Juggling Gene Therapies: Sarepta's Focus Grows, With Many Balls In The Air

 
• By Jessica Merrill

CEO Doug Ingram talked with Scrip about Sarepta's plans to quickly build out a gene therapy pipeline, potentially launch another exon-skipping drug this year and to develop micro-dystrophin for Duchenne muscular dystrophy.

Silhouette of a Woman Juggling with Balls at Sunset - Image

More from Cell Therapies

More from Advanced Therapies